Valcyte (valganciclovir) is an important antiviral medication that plays a key role in the treatment of cytomegalovirus (CMV) retinitis and the prevention of post-transplant CMV disease.
What Are the Precautions for Valcyte (valganciclovir) Administration?
Contraindications and Special Populations
(1) Valcyte is contraindicated in patients with clinically significant hypersensitivity (such as anaphylaxis) to valganciclovir or ganciclovir.
(2) Special attention should be paid to specific populations: Elderly patients should use Valcyte with caution, and dose adjustment based on renal function should be considered. Patients with renal impairment need dose reduction. Adult patients undergoing hemodialysis should not use Valcyte tablets.
Dosage Forms and Administration Methods
(1) Adult patients should use Valcyte tablets rather than the oral solution.
(2) All dosage forms of Valcyte should be taken with meals to improve bioavailability.
(3) It is particularly important to note that Valcyte tablets should not be broken or crushed to prevent unnecessary drug exposure.
Drug Interactions and Incompatibilities
(1) Concurrent use with ganciclovir and imipenem-cilastatin may trigger generalized seizures, so co-administration is not recommended.
(2) When used with cyclosporine or amphotericin B, renal function should be monitored as serum creatinine may increase. When combined with mycophenolate mofetil (MMF), patients should be monitored for hematological and renal toxicity.
(3) When co-administered with didanosine, ganciclovir may increase the plasma concentration of didanosine, and signs of didanosine toxicity such as pancreatitis need to be monitored.
(4) Concomitant use with probenecid may increase the plasma concentration of ganciclovir, so evidence of ganciclovir toxicity should be monitored.
Medication Monitoring for Valcyte (valganciclovir)
Hematological Monitoring
(1) Given that neutropenia, anemia, and thrombocytopenia frequently occur during Valcyte treatment.
(2) Complete blood counts and platelet counts should be performed frequently.
(3) This is especially important for infants and young children, patients with renal impairment, and patients who have experienced leukopenia with prior ganciclovir or other nucleoside analogues, or whose baseline neutrophil count is below 1000 cells/μL at the start of treatment.
(4) For patients with severe leukopenia, neutropenia, anemia, and/or thrombocytopenia, hematopoietic growth factors may be considered.
Special Population Monitoring
(1) Renal function should be monitored in elderly patients during use, and the dose should be adjusted accordingly.
(2) Dose adjustment is required for patients with renal impairment. The efficacy of Valcyte in patients with hepatic impairment has not been studied.
